



# Kidins220 deficiency causes ventriculomegaly via SNX27-retromer-dependent AQP4 degradation

Ana del Puerto<sup>1,2,16</sup> · Julia Pose-Utrilla<sup>1,2</sup> · Ana Simón-García<sup>1,2</sup> · Celia López-Menéndez<sup>1,2</sup> · Antonio J. Jiménez<sup>3,4</sup> · Eva Porlan<sup>5,6,7</sup> · Luis S. M. Pajuelo<sup>1,2</sup> · Guillermo Cano-García<sup>1</sup> · Beatriz Martí-Prado<sup>8</sup> · Álvaro Sebastián-Serrano<sup>1,2,17</sup> · Marina P. Sánchez-Carralero<sup>1,2</sup> · Fabrizia Cesca<sup>9</sup> · Giampietro Schiavo<sup>10,11</sup> · Isidro Ferrer<sup>2,12,13,14</sup> · Isabel Fariñas<sup>2,8</sup> · Miguel R. Campanero<sup>5,15</sup> · Teresa Iglesias<sup>1,2</sup>

Received: 14 July 2020 / Revised: 29 March 2021 / Accepted: 14 April 2021  
© The Author(s) 2021. This article is published with open access

## Abstract

Several psychiatric, neurologic and neurodegenerative disorders present increased brain ventricles volume, being hydrocephalus the disease with the major manifestation of ventriculomegaly caused by the accumulation of high amounts of cerebrospinal fluid (CSF). The molecules and pathomechanisms underlying cerebral ventricular enlargement are widely unknown. *Kinase D interacting substrate of 220 kDa (KIDINS220)* gene has been recently associated with schizophrenia and with a novel syndrome characterized by spastic paraplegia, intellectual disability, nystagmus and obesity (SINO syndrome), diseases frequently occurring with ventriculomegaly. Here we show that Kidins220, a transmembrane protein effector of various key neuronal signalling pathways, is a critical regulator of CSF homeostasis. We observe that both KIDINS220 and the water channel aquaporin-4 (AQP4) are markedly downregulated at the ventricular ependymal lining of idiopathic normal pressure hydrocephalus (iNPH) patients. We also find that Kidins220 deficient mice develop ventriculomegaly accompanied by water dyshomeostasis and loss of AQP4 in the brain ventricular ependymal layer and astrocytes. Kidins220 is a known cargo of the SNX27-retromer, a complex that redirects endocytosed plasma membrane proteins (cargos) back to the cell surface, thus avoiding their targeting to lysosomes for degradation. Mechanistically, we show that AQP4 is a novel cargo of the SNX27-retromer and that Kidins220 deficiency promotes a striking and unexpected downregulation of the SNX27-retromer that results in AQP4 lysosomal degradation. Accordingly, SNX27 silencing decreases AQP4 levels in wild-type astrocytes whereas SNX27 overexpression restores AQP4 content in Kidins220 deficient astrocytes. Together our data suggest that the KIDINS220-SNX27-retromer-AQP4 pathway is involved in human ventriculomegaly and open novel therapeutic perspectives.

## Introduction

Hydrocephalus is a disease associated with cognitive impairment where cerebrospinal fluid (CSF) accumulates provoking brain ventricular enlargement or ventriculomegaly. There are multiple hydrocephalus forms, including foetal, neonatal, paediatric and adult onset presentation, and diverse aetiologies such as genetic and

developmental factors, viral infections, co-morbidities and aging [1–4]. Although hydrocephalus is the pathology that reaches maximal brain ventricles enlargement, ventriculomegaly is also a co-morbidity factor in several psychiatric and neurodegenerative disorders, including schizophrenia [5, 6], Parkinson's disease [7] and Alzheimer's disease (AD) [8]. Dementia is one of the characteristic symptoms of chronic hydrocephalus in adults, where the major form is idiopathic normal pressure hydrocephalus (iNPH), a disease recently proposed to be neurodegenerative with dysfunctions shared with AD [9–11].

There is an urgent need to identify and characterize the pathogenic mechanisms governing CSF dynamics and underlying brain ventricular enlargement in different neuropathologies to uncover novel therapeutic strategies. Very little is known about the molecules involved in the cellular

**Supplementary information** The online version contains supplementary material available at <https://doi.org/10.1038/s41380-021-01127-9>.

✉ Teresa Iglesias  
tiglesias@iib.uam.es

Extended author information available on the last page of the article

processes that contribute to ventriculomegaly, although the water selective channel aquaporin-4 (AQP4) appears as a critical player. AQP4 expression in the brain is prominent in the basolateral membranes of ependymocytes lining cerebral ventricles and in the end-feet of astrocytes contacting brain blood vessels and the pia membrane [12, 13]. *Aqp4*<sup>-/-</sup> mice show sporadic brain ventricular enlargement, accelerated progression of induced hydrocephalus, and increased basal brain water accumulation [14–18], suggesting that AQP4 is critical for controlling whole-brain water homeostasis (reviewed in [11, 19–21]). While studies in iNPH brain revealed loss of astrocytic perivascular AQP4 [22, 23], the underlying mechanisms of AQP4 down-regulation remain unknown. It is also unknown whether AQP4 content at the ependymal ventricular lining is altered in iNPH.

The recycling of endocytosed transmembrane proteins (cargos) from early endosomes back to the plasma membrane might be involved in ventriculomegaly development, as suggested by the presence of severe postnatal hydrocephalus in mice lacking sorting nexin 27 (*Snx27*) [24]. SNX27 associated with vacuolar protein sorting 35 (VPS35), VPS29 and VPS26 forms the so-called SNX27-retromer, a complex specifically involved in the endosomal-to-plasma membrane recycling of selected cargos, that are degraded at lysosomes upon SNX27 loss [25, 26]. Importantly, retromer impairment also contributes to aberrant endocytic trafficking in various neurodegenerative diseases [27].

Kinase D interacting substrate of 220 kDa (Kidins220 [28]), also known as ankyrin-repeat rich membrane spanning (ARMS [29]), is a SNX27-retromer cargo targeted to lysosomal degradation in the absence of this PDZ protein [25]. Kidins220 is an effector of several signalling pathways, including those downstream neurotrophin and glutamate N-methyl-D-aspartate (NMDA) receptors, and modulates neuronal differentiation and synaptic activity [30, 31]. Neuronal survival depends on Kidins220 and the expression of this molecule is altered in neurological and neurodegenerative disorders, including cerebral ischemia, AD and Huntington's disease [32–36]. In addition, rare novel missense variants in *KIDINS220* gene have been associated with schizophrenia [37–39], a psychiatric disorder with a strong linkage to ventriculomegaly [5, 6]. More recently, *KIDINS220* nonsense and loss-of-function variants have been associated with SINO syndrome, a novel rare autosomal disease characterized by spastic paraplegia, intellectual disability, nystagmus and obesity, signs that concur with different degrees of ventriculomegaly [40, 41]. Here we identify Kidins220 as a key determinant in the control of brain water homeostasis, ventricular enlargement and hydrocephalus pathology by molecular mechanisms that involve the unexpected expression regulation of

SNX27-retromer components, which in turn controls AQP4 turnover.

## Materials and methods

### Human brain samples

Brain samples from iNPH patients ( $n = 6$ ) and non-normotensive hydrocephalus patients ( $n = 3$ ), and control subjects ( $n = 8$ ) (for data see Supplementary Table 1) were obtained from the Institute of Neuropathology Brain Bank (IDIBELL, Hospitalet de Llobregat, Spain), tissue Biobank from Hospital Clinic de Barcelona and Institute d'Investigacions Biomediques August Pi I Sunyer (HCB-IDIBAPS Biobank), and the Biobank Banco de Tejidos CIEN (PT17/0015/0014), integrated into the Spanish National Biobanks Network following Spanish legislation and local Ethics Committee guidelines and processed following standard operating procedures as described [42]. Briefly, one brain hemisphere was fixed by immersion in 4% buffered formalin for 3 weeks. Samples of selected regions of the brain were embedded in paraffin and 15- $\mu$ m sections were stained for neuropathological studies using immunohistochemistry methods (see 'Immunohistochemistry of mouse and human brain samples' section and details for antibodies and dilutions used in Supplementary Table 2). All participants gave their written consent, and the study was approved by the local Ethics and Scientific Committees following the ethical standards recommended by the Helsinki Declaration.

### Experimental animals

*Kidins220*<sup>ff</sup> mice and *Kidins220*<sup>-/-</sup> mice in C57BL/6J background had been previously generated in G. Schiavo laboratory [43]. Male and female 2-month-old *Kidins220*<sup>+/ff</sup>, *Kidins220*<sup>ff/ff</sup> or WT littermates were employed in independent experiments for comparison purposes. Genotyping was performed by PCR using specific pairs of primers [43]. All animals were produced and housed at the animal care facility at Instituto de Investigaciones Biomédicas 'Alberto Sols' (IIBM, CSIC-UAM, Madrid, Spain) and maintained under 12/12 h light-dark cycle and with access to food and water *ad libitum* in a temperature-controlled environment. Overall mouse health was assessed by daily inspection for signs of discomfort, weight loss or changes in behaviour, mobility and feeding or drinking habits. Procedures involving animals had been approved by Institutional (IIBM and CSIC) and local Ethical Committees, and were conformed to the appropriate national legislations (RD 53/2013) and the guidelines of the European Commission for the accommodation and care of laboratory animals (revised in Appendix A of the Council of Europe Convention ETS123).

Magnetic resonance imaging; Scanning electron microscopy; RNA isolation, reverse transcription and quantitative real-time PCR; Plasmids; Cell culture, treatment and transfection of primary cortical astrocytes and HEK293T cells; Lentiviral production and transduction of astrocytic cultures; Water permeability and cell-volume measurements in cultured astrocytes; Commercial antibodies; Preparation of protein extracts, immunoprecipitation and immunoblot analysis; Immunofluorescence of cultured astrocytes; Immunohistochemistry of mouse and human brain samples; Image acquisition and Quantitative and statistical analysis were performed as described in the Extended Data Supplementary Material and Methods section. Pairs of primers for quantitative real-time PCR and sh-oligonucleotides cloned in lentiviral vectors are detailed in Supplementary Table 3.

## Results

### *Kidins220* deficient mice present ventriculomegaly


Because *Kidins220* complete ablation produces perinatal lethality, we created *Kidins220-floxed* mice to generate mouse models with a conditional deletion in different tissues and cells to study this molecule function in adulthood [43, 44]. We noticed that homozygous *Kidins220-floxed* mice (*Kidins220<sup>ff</sup>*) were not present in the offspring of heterozygous (*Kidins220<sup>+ff</sup>*) crosses at Mendelian ratio, with a greater lethality at weaning (Fig. 1A, B). Two-month-old *Kidins220<sup>ff</sup>* animals did not show differences in body weight but presented an increment in brain weight compared to their littermates (Supplementary Fig. S1a). It was also visually apparent that a low percentage of *Kidins220<sup>ff</sup>* mice presented encephalomegaly (17.4%), referred to as ‘severe’ (S) (*Kidins220<sup>ff(S)</sup>*), suggesting possible brain ventricular enlargement and hydrocephalus (Fig. 1C). MRI analysis confirmed the development of ventriculomegaly to various extents, from mild to severe, both in male and female *Kidins220<sup>ff</sup>* mice (Fig. 1D and Supplementary Fig. S1b). Volumetric quantification from T2-weighted (T2-W) images rendered increments in the volume of lateral ventricles (LVs) and third ventricle (TV) of male and female *Kidins220<sup>ff</sup>* animals compared to wild type (WT) or *Kidins220<sup>+ff</sup>* littermates (Fig. 1D and Supplementary Fig. S1b). While no substantial changes were detected in the fourth ventricle (FV), the aqueduct of Sylvius (SA) volume was decreased in *Kidins220<sup>ff</sup>* males and females (Fig. 1D and Supplementary Fig. S1b). Using diffusion-weighted imaging MRI, we also calculated apparent diffusion coefficient (ADC) values as a measurement of the magnitude of diffusion of water molecules in the ventricles and SA of male mice. ADC values were

elevated in LVs and TV from *Kidins220<sup>ff</sup>* mice relative to WT animals suggesting an imbalance in the circulation of CSF (Fig. 1E).

The generation of *Kidins220<sup>ff</sup>* animals involved genetic manipulations that integrated *Kidins220* cDNA within exon 16 of the mouse gene (see details in reference [43] and scheme in Supplementary Fig. S1c). We hypothesized that this strategy might potentially cause a deficiency in *Kidins220* expression. To test this hypothesis, we analysed *Kidins220* levels in various brain regions. Peroxidase-based immunostaining of brain slices detected lower *Kidins220* signal intensity in *Kidins220<sup>ff</sup>* compared to WT mice (Supplementary Fig. S1d). Immunoblot analysis showed that the cortex and cerebellum of *Kidins220<sup>ff</sup>* mice exhibited decreased amounts of *Kidins220* compared to WT animals (Fig. 1F). The cortex of *Kidins220<sup>+ff</sup>*, but not the cerebellum, also presented substantially reduced levels of this protein, indicating that some brain regions are potentially more susceptible to the interference induced by the transgenic modification. Importantly, we found an inverse correlation between *Kidins220* levels and LVs and TV ventricular volume in WT, *Kidins220<sup>+ff</sup>*, and *Kidins220<sup>ff</sup>* mice (Fig. 1G), suggesting that *Kidins220* deficiency and brain ventricle enlargement are strongly linked. In addition to brain, extracts obtained from several tissues showed decreased levels of *Kidins220* to various degrees between WT, *Kidins220<sup>+ff</sup>*, and *Kidins220<sup>ff</sup>* mice (Supplementary Fig. S1e). *Kidins220<sup>ff(S)</sup>* mice were sacrificed immediately after MRI, and their brain tissue was not further analysed due to the high degree of damage (see MRI of a highly severe phenotype in Supplementary Fig. 2). Together, these data indicate that *Kidins220<sup>ff</sup>* mice constitute a hypomorphic model with marked deficiency of *Kidins220* in several tissues, supporting the notion that the decrease of *Kidins220* brain levels is linked to ventriculomegaly and hydrocephalus development.

### Loss of *Kidins220* and AQP4 at the ventricular ependyma of *Kidins220* hydrocephalus mice and human iNPH patients

Due to the importance of the ventricular ependyma in brain water homeostasis and congenital hydrocephalus [3], we examined the presence of *Kidins220* in this specialised tissue by using a recently generated antibody [45]. Its specificity in immunofluorescence and immunoblot analyses was further validated by antibody neutralization with the immunizing peptide and by using brain tissue from *Kidins220<sup>-/-</sup>* mice [43, 44] (Supplementary Fig. S3a–c). Confocal microscopy analysis showed higher ependymal *Kidins220* expression in the lateral ventricles of WT mice compared to *Kidins220<sup>ff</sup>* mice (Fig. 2A). Accordingly,



Kidins220 levels were significantly lowered in extracts prepared from the lateral periventricular area (PVA) of *Kidins220<sup>fl/fl</sup>* animals (Fig. 2B).

The ependymal barrier lines cerebral ventricles and is formed by multiciliated ependymocytes that beat ventricular CSF synchronously to drive its unidirectional flow across ventricles [46, 47]. Different types of congenital

hydrocephalus present developmental defects in ependymocytes differentiation, ciliogenesis and maturation, or denudation of the ependymal barrier [3, 48]. We, therefore, examined the morphological features of the ependymal cells in LVs of 2-month-old *Kidins220<sup>fl/fl</sup>* mice by scanning electron microscopy, finding no apparent macroscopic changes in their cilia compared to WT animals



◀ **Fig. 1 Ventriculomegaly in *Kidins220* hypomorphic mice.** **A** Total number ( $n = 232$ ) and percentage of WT, *Kidins220*<sup>fl/+</sup> and *Kidins220*<sup>fl/fl</sup> mice alive at weaning vs their expected Mendelian ratio. **B** Percentage of WT, *Kidins220*<sup>fl/+</sup> and *Kidins220*<sup>fl/fl</sup> mice death at weaning showing severe hydrocephalic phenotype ( $n = 232$ ). **C** Representative images of 2-month-old WT, *Kidins220*<sup>fl/fl</sup>, and severely hydrocephalic *Kidins220*<sup>fl/fl</sup> (*Kidins220*<sup>fl(S)</sup>) mice. Right: Zoom detail of the head. **D** Representative in vivo T2-weighted (T2-W) MRI coronal images showing lateral and third ventricles (LVs + TV; left panels), aqueduct of Sylvius (SA; central panels—dotted line) and fourth ventricle (FV; right panels—dotted line) of 2-month-old WT, *Kidins220*<sup>fl/+</sup>, *Kidins220*<sup>fl/fl</sup> and *Kidins220*<sup>fl(S)</sup> male mice. Scale bar, 1 mm. Quantification of ventricular and aqueduct volume (mm<sup>3</sup>) in 17 WT (circles), 6 *Kidins220*<sup>fl/+</sup> (squares) and 14 *Kidins220*<sup>fl/fl</sup> (triangles) mice. LVs and TV values from the same group of 17 WT (circles) animals have been represented in a separate graph with those of three severe *Kidins220*<sup>fl(S)</sup> (diamonds) mice. **E** Apparent Diffusion Coefficient (ADC) representative coronal images showing LVs and TV (left panels), SA (central panels—dotted line) and FV (right panels—dotted line) of 2-month-old WT, *Kidins220*<sup>fl/fl</sup> and *Kidins220*<sup>fl(S)</sup> male animals. The pseudo-colour scale indicates maximum and minimum ADC values in  $\mu\text{m}^2/\text{s}$ . Scale bar, 1 mm. Quantification of ADC values ( $\mu\text{m}^2/\text{s}$ ) at the ventricles and aqueduct in WT (circles; LVs, TV and SA,  $n = 16$ ; FV,  $n = 12$ ), *Kidins220*<sup>fl/fl</sup> (triangles; LVs, TV and SA,  $n = 12$ ; FV,  $n = 8$ ) and *Kidins220*<sup>fl(S)</sup> ( $n = 3$ , diamonds) mice. **F** Representative *Kidins220* and  $\alpha$ -tubulin (loading control) immunoblots of cortex (Cx) and cerebellum (Cb) lysates from WT, *Kidins220*<sup>fl/+</sup> and *Kidins220*<sup>fl/fl</sup> mice; each lane represents one animal. *Kidins220* levels are represented in arbitrary units after normalization with  $\alpha$ -tubulin in *Kidins220*<sup>fl/+</sup> (Cx,  $n = 6$ ; Cb,  $n = 4$ ) and *Kidins220*<sup>fl/fl</sup> (Cx,  $n = 6$ ; Cb,  $n = 5$ ) relative to WT (Cx,  $n = 7$ , Cb,  $n = 4$ ) mice. **G** Correlation between *Kidins220* relative levels in the cortex (Cx, left panel) and cerebellum (Cb, right panel) represented in (F) and LVs and TV volumes quantified in T2-W MRI images depicted in (D), established by linear regression analysis (Cx,  $R^2: 0.5954$ ; Cb,  $R^2: 0.6231$ ). **D, E, F** Data are mean  $\pm$  s.e.m.; each data point denotes an individual mouse; NS not significant; \*\*\* $P < 0.001$ , by one-way ANOVA (D, F) and two-tailed unpaired Student's  $t$  test (E).

(Supplementary Fig. S4a). In addition, organization and integrity of the ependymal barrier in *Kidins220* deficient mice was largely unaltered, as assessed by whole-mount preparation immunostaining and localization of  $\beta$ -catenin at the intercellular contacts and  $\gamma$ -tubulin at the base of the cilia (Supplementary Fig. S4b).

Although the ultrastructural appearance and planar polarity of the ependymal barrier in *Kidins220*<sup>fl/fl</sup> animals were normal, ependymal cells lacked expression of S100 calcium-binding protein  $\beta$  (S100 $\beta$ ), a protein expressed in ependymocytes and astrocytes [49] (Fig. 2C). We also examined levels of AQP4 in this area as this channel is also expressed in ependymal cells and plays a critical role in brain water homeostasis and ependyma function [19, 20]. *Kidins220*<sup>fl/fl</sup> mice exhibited a striking downregulation of AQP4 in ependymal cells of LVs compared to WT animals, in immunofluorescence analysis of both brain sections and whole-mount preparations (Fig. 2D and Supplementary Fig. S4c). In contrast, no substantial changes in GFAP, a marker for neural stem cells and astrocytes, or FoxJ1 that


marks mature ciliated ependymal cells [50, 51] were observed (Supplementary Fig. S4d, e).

Next, we examined potential decreases of KIDINS220 and AQP4 at the ventricular ependyma in iNPH patients compared to control donors (Supplementary Table 1). We found that ependymal cells were positive for KIDINS220 signal in brain necropsies from control individuals and that this staining diminished significantly in samples from equivalent brain regions from iNPH patients (Fig. 2E and Supplementary Fig. S5a–S6). Samples from adult non-normotensive hydrocephalus (Hyd) patients similarly presented a fainter KIDINS220 ependymal barrier signal than aged-matched controls (Fig. 2E and Supplementary Fig. S5a–S6). By contrast, S100 $\beta$  ependymal zone immunolabelling was unaltered in hydrocephalic versus control human samples (Supplementary Fig. S5b). Notably, AQP4 immunofluorescence analysis also showed a sharp signal drop in samples from iNPH patients (Fig. 2F and Supplementary Fig. S5c). This is the first evidence of an ependymal deficit of AQP4 and KIDINS220 in iNPH patients, supporting the involvement of the ependymal barrier and these two molecules in the development of adult chronic hydrocephalus.

### Downregulation of AQP4 in astrocytes from *Kidins220* hypomorphic mice

To gain mechanistic insight into the regulation of S100 $\beta$  and AQP4 expression by *Kidins220*, we analysed primary cultures of astrocytes because these cells contain high levels of these two molecules and, in contrast to ependymocytes, can be readily cultured, maintained and transfected/transduced in vitro. RTq-PCR showed no significant decreases of *Aqp4* or *S100 $\beta$*  mRNA in cultured astrocytes or in tissue from the PVA obtained from *Kidins220*<sup>fl/fl</sup> animals (Supplementary Fig. S7). However, we observed a substantial decrease in *Kidins220* and AQP4 in cultured astrocytes obtained from *Kidins220*<sup>fl/fl</sup> mice (Fig. 3A, B), suggesting that post-transcriptional mechanisms underlie AQP4 downregulation. Of note, we could not detect S100 $\beta$  protein.

Astrocytes transiently increase their volume upon hypotonic stress and this process is regulated by AQP4 [52]. To determine whether AQP4 function is impaired in *Kidins220*<sup>fl/fl</sup> astrocytes, we treated astrocytes with a hypotonic stimulus and measured their volume by using the calcein-quenching assay [52]. We found that *Kidins220*<sup>fl/fl</sup> astrocytes did not increase their volume as much as WT cells upon hypotonic stress, and showed a significant delay in bringing their volume back to baseline (Fig. 3C–E). These results strongly suggest that AQP4 function is greatly hampered in *Kidins220* deficient astrocytes.




**Fig. 2** Decreased AQP4 and Kidins220 levels at the ependymal barrier of *Kidins220* hypomorphic mice and human iNPH. **A** Representative confocal microscopy images of Kidins220 (green) and DAPI (blue) staining at the ependymal barrier of brain lateral ventricles (LV) of 2-month-old WT and *Kidins220*<sup>ff</sup> mice, and (right panel) quantification of Kidins220 immunostaining at the ependymal barrier of 4 *Kidins220*<sup>ff</sup> mice relative to 3 WT mice. Scale bar, 50  $\mu$ m. **B** Kidins220 and  $\alpha$ -tubulin (loading control) immunoblot analysis of the periventricular area (PVA) of WT and *Kidins220*<sup>ff</sup> mice ( $n = 4$  per genotype); each lane represents one mouse. Kidins220 levels, after normalization with those for  $\alpha$ -tubulin, were represented relative to WT mice (bottom panel). **C**, **D** Representative confocal microscopy images showing S100 $\beta$  (**C**), AQP4 (**D**) immunostaining (green) and DAPI nuclear labelling (blue) of lateral ventricles (LV) ependymal barrier from 2-month-old WT and *Kidins220*<sup>ff</sup> mice. Scale bar, 50  $\mu$ m. Quantification of S100 $\beta$  (**C**;  $n = 7$  animals per genotype) and AQP4

(**D**;  $n = 6$  WT and  $n = 7$  *Kidins220*<sup>ff</sup> mice) staining at the ependymal barrier of *Kidins220*<sup>ff</sup> mice relative to WT mice. **E**, **F** Representative confocal microscopy images of KIDINS220 (**E**) and AQP4 (**F**) immunostaining (green) and DAPI nuclear labelling (blue) at the ependymal barrier (dotted lines) of necropsies from iNPH patients and control subjects. Scale bars, 30  $\mu$ m. Quantification of ependymal barrier immunostaining in human postmortem samples from hydrocephalic patients relative to control individuals: KIDINS220 (**E**) [iNPH  $n = 6$ ; Hyd  $n = 3$ ; control  $n = 8$ ] and AQP4 (**F**) [iNPH  $n = 3$ ; control  $n = 3$ ]. For quantifications, three sections per animal and genotype and 3 ROIs per section (**A**, **C**, **D**), and 9 randomly selected ROIs per human section (**E**, **F**) were used; data are mean  $\pm$  s.e.m.; each data point denotes an individual mouse/subject. (**A–F**)  $*0.01 < P < 0.05$ ,  $**0.001 < P < 0.01$ ,  $***P < 0.001$ ; by two-tailed unpaired Student's  $t$  test.

We then investigated the potential post-transcriptional mechanisms involved in AQP4 downregulation. As this water channel can be degraded by the lysosome [53], we examined the effect of the vATPase inhibitor bafilomycin A1 on AQP4 levels. We found that bafilomycin A1 induced a significant

increase in AQP4 levels both in WT and *Kidins220*<sup>ff</sup> astrocytes, as determined by immunofluorescence analysis and immunoblot quantification (Fig. 3F, G). Together, our data strongly suggest that *Kidins220* deficiency increases AQP4 lysosomal degradation.



### Joint regulation of the SNX27-retromer and its novel cargo AQP4 by Kidins220

Given that Kidins220 endosomal recycling to the cell surface is controlled by the SNX27-retromer complex [25], and that *Snx27* genetic inactivation causes severe postnatal hydrocephalus in mice [24], we investigated whether hydrocephalus development in *Kidins220* deficient animals

could be associated with SNX27-retromer dysfunction. Staining of VPS35, the key SNX27-retromer component [26], and SNX27 at the ependyma of LVs revealed a prominent decrease of their levels in *Kidins220<sup>ff</sup>* (Fig. 4A). Accordingly, astrocytes from *Kidins220<sup>ff</sup>* mice also showed a severe downregulation of SNX27 and VPS35 (Fig. 4B). We then checked whether Kidins220 could be directly involved in the control of SNX27 and VPS35 by



◀ **Fig. 3 AQP4 downregulation in Kidins220-deficient astrocytes is rescued by inhibition of lysosomal degradation.** **A** Representative confocal microscopy images of AQP4 (green), GFAP (red) and DAPI (blue) staining of primary cortical astrocytes dissected from WT ( $n = 3$ ) and *Kidins220*<sup>ff</sup> ( $n = 3$ ) mice. Scale bar, 50  $\mu\text{m}$ . **B** (top panels) Kidins220, AQP4 and GFAP (loading control) immunoblot analyses of WT and *Kidins220*<sup>ff</sup> cortical astrocytes; each lane represents a culture obtained from one animal. (bottom panels) Kidins220 and AQP4 levels in *Kidins220*<sup>ff</sup> astrocytes expressed in arbitrary units after normalization with GFAP and relative to WT astrocytes ( $n = 4$  of each genotype). **C–E** Primary astrocytes from WT ( $n = 3$ ) and *Kidins220*<sup>ff</sup> ( $n = 3$ ) mice were exposed to a hypotonic medium ( $\Delta\text{Osm} = 150$  and  $75$  mOsm) ( $n = 3$  independent experiments); **C** Calcein-quenching measurement of osmotically induced volume changes in these cells ( $n = 6$  of each genotype) during 300 s after a basal recording of 60 s. **D** Quantitative analysis of the initial volume increase osmotically induced in 7 WT and 14 *Kidins220*<sup>ff</sup> astrocytes from calcein-quenching measurement data; ordinate values represent mean volume changes at 65 s and 170 s (Ft) of hypotonic stress relative to WT baseline levels (Ft0). **E** Representation of the final volume osmotically induced changes in 8 WT and 12 *Kidins220*<sup>ff</sup> astrocytes from calcein-quenching measurement data; ordinate values represent mean volume changes incurred between the maximum volume at 170 s (Ft170) and the one registered at 300 s, at the end of the recording period (Ft300) to examine recovery capacity. See ‘Materials and Methods’ for quantification details. Regulatory volume decreases (RVD) indicative of volume recovery are represented by negative values. **F** Representative confocal microscopy images of AQP4 (green), GFAP (red) and DAPI (blue) staining of cultured astrocytes from WT and *Kidins220*<sup>ff</sup> mice incubated with vehicle (Control) or bafilomycin A1 for 16 h. Scale bar; 50  $\mu\text{m}$ . Quantification of AQP4 immunostaining in GFAP-positive astrocytes under the indicated conditions; each data point represents a single astrocyte ( $n = 60\text{--}80$  astrocytes per condition;  $n = 3$  independent experiments). **G** Representative Kidins220, AQP4 and GFAP (loading control) immunoblot analysis of cultured cortical astrocytes incubated with vehicle (–) or bafilomycin A1 (Baf, +) obtained from WT and *Kidins220*<sup>ff</sup> mice. Quantification of Kidins220 and AQP4 levels after normalization with GFAP signal ( $n = 5$  independent experiments) and relative to WT cells is shown (bottom panels). Quantification data are shown as mean  $\pm$  s.e.m.; NS not significant; \*\* $0.001 < P < 0.01$ , \*\*\* $P < 0.001$ ; by two-tailed unpaired Student’s  $t$  test in (B, D, E) and two-way ANOVA in (F, G).

transducing cultured astrocytes from WT mice with lentiviral particles encoding *Kidins220* shRNA (sh*Kidins220*, referred as shK) or a control shRNA (shC). Strikingly, *Kidins220* knockdown strongly reduced SNX27 protein levels without altering those of VPS35 (Fig. 4C). Consistent with results obtained in *Kidins220*<sup>ff</sup> astrocytes, *Kidins220* silencing similarly decreased AQP4 content (Fig. 4C).


Subcellular distribution of SNX27 was apparently preserved in *Kidins220*<sup>ff</sup> astrocytes (Supplementary Fig. S8). In addition, analysis of the early endosomal marker Rab5 revealed no substantial differences in *Kidins220*<sup>ff</sup> astrocytic endosomal network (Supplementary Fig. S9). Together these data suggest that the early endosomal compartment is not globally affected by *Kidins220* deficiency. The retromer-independent SNX17

[54] remained constant as well, both in *Kidins220*<sup>ff</sup> and *Kidins220* silenced astrocytes (Supplementary Fig. S10), supporting the specificity of *Kidins220* deficiency on retromer regulation.

The loss of SNX27 and VPS35 in *Kidins220*<sup>ff</sup> deficient astrocytes, contrary to that of AQP4, was not rescued by bafilomycin A1 treatment (Supplementary Fig. S11a). In addition, *Snx27* and *Vps35* mRNA levels did not decrease in PVA tissue or cultured astrocytes from *Kidins220*<sup>ff</sup> mice, while *Vps35* transcripts only increased slightly in the glial cells in vitro (Supplementary Fig. S11b, c), suggesting that post-transcriptional regulation mechanisms distinct from lysosomal degradation mediate *Kidins220*-dependent SNX27 and VPS35 downregulation.

*Kidins220* is considered as a canonical cargo for the SNX27-retromer and its type I postsynaptic density-95/discs large/zonula occludens-1 (PDZ)-binding motif or ligand (PDZ-L) has been classified as a bona fide ligand for SNX27 PDZ domain [25, 55]. Notably, AQP4 bears a PDZ-L that is fundamental for its localization at the plasma membrane in astrocytes [56, 57]. AQP4 PDZ-L is evolutionarily conserved (Fig. 4D) and highly similar to that of *Kidins220* and other known SNX27 cargos (Fig. 4E), suggesting that AQP4 could be a cargo for the SNX27-retromer. In this scenario, it was feasible that SNX27 downregulation in *Kidins220*<sup>ff</sup> mice could lead to lysosomal processing of AQP4 in astrocytes, as it occurs with *Kidins220* after SNX27 loss in tumour cells [25]. However, alignment of AQP4 PDZ-L sequence with those from consensus SNX27-retromer cargos, including *Kidins220*, showed an apparently important mismatch at the acidic clamp for SNX27 interaction [55] (Fig. 4E). To address whether AQP4 could be a cargo for the SNX27-retromer, we first analysed the cellular sub-localization of AQP4 and some components of this complex in cultured astrocytes from WT mice. Confocal microscopy imaging showed co-localization of AQP4 not only with SNX27 but also with VPS35 (Fig. 4F) and *Kidins220* (Supplementary Fig. S12). Moreover, AQP4 was present in VPS35-immunocomplexes obtained from murine cerebral cortex and cultured primary astrocytes (Fig. 4G). We could not use SNX27 antibodies for co-immunoprecipitation experiments due to the difficulty of distinguishing the SNX27 band from that of the immunoglobulin heavy chain in the immunoblot analysis. In addition, we examined AQP4 association to the SNX27-retromer by transfecting HEK293T cells with plasmids encoding AQP4, full-length SNX27 (SNX27-FL) or a mutant lacking its PDZ-domain (SNX27- $\Delta$ PDZ), all fused to GFP. Analysis of endogenous VPS35-immunoprecipitates revealed they contained AQP4 (Fig. 4H). Co-expression of SNX27-FL is compatible with the association of AQP4 with VPS35-immunocomplexes but co-expression of SNX27- $\Delta$ PDZ





disrupted this binding (Fig. 4H). Complementary experiments showed that mCherry-SNX27 was present in GFP-AQP4 immunoprecipitates (Supplementary Fig. S13). Together, these data indicate that the PDZ domain of SNX27 is necessary for the association of AQP4 with VPS35 and that AQP4 is a novel cargo for the SNX27-retromer.

### Kidins220-dependent AQP4 downregulation is mediated by SNX27

To investigate whether SNX27 downregulation mediates the decrease of AQP4 levels caused by Kidins220 deficiency, we generated lentiviral particles for SNX27 silencing in WT cultured astrocytes (Supplementary

**◀ Fig. 4 Joint regulation of the SNX27-retromer and its novel cargo AQP4 by Kidins220.** **A** Representative confocal microscopy images of AQP4 (green), SNX27 (red), VPS35 (magenta) and DAPI (blue) staining of the ependymal barrier from lateral ventricles (LV) of WT ( $n = 5$ ) and *Kidins220<sup>ff</sup>* ( $n = 7$ ) mice; and (right panel) quantification of SNX27 and VPS35 staining of these samples (three sections per animal). Scale bar, 50  $\mu$ m. **B** Kidins220, SNX27, VPS35 and GFAP (loading control) immunoblot analyses of WT and *Kidins220<sup>ff</sup>* cortical astrocytes; each lane represents a culture obtained from one animal. Graphs represent the quantification of SNX27 and VPS35 after normalization with GFAP. **C** Kidins220, SNX27, AQP4, VPS35 and  $\alpha$ -tubulin (loading control) immunoblot analyses of cultured cortical astrocytes obtained from WT mice transduced with lentivirus encoding shControl (shC) or shKidins220 (shK). Quantification of the indicated protein levels after normalization with  $\alpha$ -tubulin: Kidins220 ( $n = 3$ ), SNX27 ( $n = 3$ ), AQP4 ( $n = 4$ ) and VPS35 ( $n = 3$ ) independent experiments. **D** Sequence alignment of the last 9 amino acids within AQP4 C-terminal end of different organisms and their access number. **E** Sequence alignment of the last 8 amino acids of human AQP4 and the indicated known cargos of SNX27. PDZ-binding motif triplet residues (PDZ-L) are shown in grey boxes and critical amino acids at 0 and -2 position are labelled in blue. Negatively charged amino acids (aspartic and glutamic acid or phosphorylated serine, threonine residues) at -3 and -5 position enhancing SNX27 binding by forming an acidic clamp are shown in magenta. Note that in -3 position there is a leucine within AQP4 sequence or isoleucine within PTEN, and in the -5 position there is a glycine within GLUT1 and a cysteine within OCLUDIN (labelled in red). **F** Representative confocal microscopy images showing AQP4 (green), SNX27 (red), VPS35 (magenta) and DAPI (blue) staining in cultured WT astrocytes ( $n = 3$  independent experiments). Scale bar, 50  $\mu$ m. Zoom images from boxed regions are also shown. Scale bar, 5  $\mu$ m. **G** Representative immunoprecipitation (IP) analysis of VPS35 in lysates from cortical cultured astrocytes or cortex (Cx) from WT mice and immunoblotting with VPS35 or AQP4 antibodies. Immunoprecipitation with a non-related immunoglobulin (IgG) was used as control. Total lysates (TL) were run in parallel ( $n = 3$  independent experiments). Low and high exposure images of AQP4 in cortical lysates are included. **H** VPS35 was immunoprecipitated in lysates from HEK293T cells transfected with GFP or GFP-AQP4 and GFP-SNX27 full-length (SNX27-FL) or GFP SNX27 lacking the PDZ domain (SNX27- $\Delta$ PDZ). Representative immunoblot analysis of total lysates (TL) or VPS35-immunoprecipitates (IP VPS35) using GFP, AQP4 or VPS35 antibodies. Low and high exposures of GFP and AQP4 immunoblots are shown in order to analyse properly bands signal ( $n = 3$  independent experiments). Quantification data are shown as mean  $\pm$  s.e.m.; NS not significant, \* $0.01 < P < 0.05$ , \*\* $0.001 < P < 0.01$ ; by two-tailed unpaired Student's *t* test (**A**, **B**, **C**).


Fig. S14a). Transduction of astrocytes with shSNX27-1 or -2 lentivirus sharply decreased AQP4 content, as assessed by immunofluorescence and quantitative immunoblot analysis (Fig. 5A, B and Supplementary Fig. S14b, c). Note that SNX27 knockdown also diminished significantly ( $P < 0.001$ ) Kidins220 protein levels in astrocytes (Fig. 5B and Supplementary Fig. S14c), as previously observed in HeLa cells [25]. In addition, AQP4 levels were restored after lysosomal inhibition by bafilomycin treatment in SNX27-silenced astrocytes (Supplementary Fig. S14d). Conversely, forced SNX27 expression in *Kidins220<sup>ff</sup>* astrocytes substantially increased AQP4 expression (Fig. 5C). Of note, AQP4 colocalized with ectopic SNX27 in Rab5+

endosomes (Supplementary Fig. S15). Together our data support the notion that Kidins220 deficiency causes SNX27 and VPS35 loss that in turn mediates AQP4 lysosomal degradation and water dyshomeostasis (see scheme in Fig. 5D).

## Discussion

Here we have uncovered Kidins220-SNX27-retromer as a regulatory pathway for brain AQP4 expression and its involvement in brain ventricular enlargement and hydrocephalus. We have identified a surprising link between SNX27-retromer down-regulation and AQP4 lysosomal degradation induced by Kidins220 deficiency, and discovered that KIDINS220 and AQP4 expression is sharply decreased at the ependymal barrier in iNPH patients. We also show that hypomorphic *Kidins220<sup>ff</sup>* mice are a novel mouse model of hydrocephalus that display ventriculomegaly and a marked AQP4 downregulation in brain astrocytes and in the ependymal cells lining lateral ventricles, without apparent ependymocytes structural organization and ciliogenesis impairment.

The *Kidins220* hypomorphic mouse model shows various degrees of Kidins220 downregulation that positively correlate with ventriculomegaly penetrance. The decrease in the number of *Kidins220<sup>ff</sup>* mice at weaning might be attributed to embryonic or perinatal hydrocephalus-associated death of mice with high downregulation of Kidins220. Supporting this hypothesis, constitutive *Kidins220<sup>-/-</sup>* mice die at birth and their brains present a pronounced ventricular enlargement [43]. The majority of *Kidins220<sup>ff</sup>* born mice reached adulthood without showing apparent external evidence of overt hydrocephalus, suggesting that ventricle enlargement progresses slowly in these animals. While the brain of *Kidins220<sup>-/-</sup>* embryos presents a pronounced enlargement of LVs, TV and FV [43], 2-month-old *Kidins220<sup>ff</sup>* animals only show enlargement of the LVs and TV. These results suggest an incipient nature of hydrocephalus in 2-month-old *Kidins220<sup>ff</sup>*, which might develop progressively with aging. Ventriculomegaly in these mice resembles that observed in *Aqp4<sup>-/-</sup>* animals, which show sporadic progressive obstructive hydrocephalus with LVs and TV enlargement and aqueduct stenosis, without severe changes in FV volume and mild ependymal disorganization [14, 58]. In contrast, ependymal-conditional *Aqp4<sup>-/-</sup>* mice reveal no abnormalities in the ependymal lining and do not present changes in brain ventricular volume or increased brain water content, at least at the age studied [18]. A possibility is that ependymal-conditional *Aqp4<sup>-/-</sup>* mice could develop ventricular enlargement during aging, a study that is indeed missing. Alternatively, these data could suggest that



ventriculomegaly in *Kidins220<sup>fl/fl</sup>* mice might rely not only on AQP4 downregulation but also on changes in additional molecules.

Constitutive *Snx27<sup>-/-</sup>* mice develop severe hydrocephalus soon after birth, showing ependymal deciliation and differentiation defects with complete penetrance [24]. These mice could show a more severe phenotype than

*Kidins220<sup>fl/fl</sup>* animals because the latter do not completely lack SNX27, thus sparing its cargos from complete lysosomal degradation.

A very recent publication, that does not study AQP4, describes that young postnatal *Vps35* conditional KO mice develop neonatal hydrocephalus, similar to that of *Snx27<sup>-/-</sup>* mice, with deficient ependymal cells differentiation and



◀ **Fig. 5 AQP4 downregulation by Kidins220 deficiency is mediated by SNX27.** **A** Representative confocal microscope images of GFP (green), SNX27 (red), AQP4 (magenta) and DAPI (blue) staining of cultured astrocytes transfected with plasmids encoding GFP and shC or shSNX27 (1 and 2). Scale bar 50  $\mu$ m. (Lower panels) Quantification of SNX27 and AQP4 fluorescence intensity in GFP<sup>+</sup> astrocytes in each condition is shown relative to shC-transfected cells ( $n = 20$ – $30$  astrocytes per condition;  $n = 3$  independent experiments); each data point represents a single astrocyte. **B** Representative SNX27, AQP4, Kidins220 and GFAP (loading control) immunoblot analyses of cortical astrocytes from WT mice transduced with shC- or shSNX27-1-encoding lentivirus. Quantification of AQP4, SNX27 and Kidins220 levels after normalization with GFAP is shown relative to shC values ( $n = 4$  independent experiments). **C** Representative confocal microscopy images of GFP (green), SNX27 (red), AQP4 (magenta) and DAPI (blue) staining of cultured astrocytes from WT or *Kidins220*<sup>ff</sup> mice transfected with plasmids encoding GFP or SNX27-GFP. Scale bar 50  $\mu$ m. Quantification of AQP4 and SNX27 fluorescence intensity in GFP<sup>+</sup> astrocytes is shown relative to shC-transfected cells (40–60 astrocytes per condition;  $n = 3$  independent experiments); each data point represents a single astrocyte. Quantification data are mean  $\pm$  s.e. m.; NS not significant; \* $0.01 < P < 0.05$ , \*\* $0.001 < P < 0.01$ , \*\*\* $P < 0.001$ ; by one-way ANOVA (A), two-tailed unpaired Student's *t* test in (B) and by two-way ANOVA (C). **D** Scheme illustrating the role of Kidins220 in the control of AQP4 through SNX27 downregulation. In the presence of Kidins220, AQP4 levels are preserved by the interaction with the SNX27-retromer that favours AQP4 endosomal recycling to the plasma membrane. In the absence of Kidins220, SNX27 and VPS35 levels decrease drastically and AQP4 is targeted for lysosomal degradation, consequently leading to brain water dyshomeostasis and contributing to the development of ventriculomegaly and hydrocephalus.

gliogenesis [59]. As in *Kidins220*<sup>ff</sup> animals, S100 $\beta$  is downregulated in the ependymal barrier of *Vps35*-deficient mice. Locally activated microglia seems to be responsible for ependymal cells dyshomeostasis provoked by VPS35 loss, as pathology diminishes following microglia depletion [59]. A similar environment, with activated microglia exerting cell non-autonomous effects might be found in *Kidins220*<sup>ff</sup> ependymal barrier where VPS35 levels are also severely decreased. Alternatively, as ependymal cells precursors are S100 $\beta$  negative and mature ependymal cells are S100 $\beta$  positive, the lack of S100 $\beta$  staining might indicate changes in the different cell populations at the ependymal barrier in *Kidins220* deficient animals. Future studies to analyse in detail the different cellular subtypes that constitute the ventricular and subventricular zones (i.e. number of precursors and their proliferation) or the presence of activated microglia will be of high interest. Cell non-autonomous effects might also modify the nature of astrocytes in *Kidins220*<sup>ff</sup> brain that may retain these altered features when cultured in vitro. This scenario would explain why VPS35 levels are decreased in cultured *Kidins220*<sup>ff</sup> astrocytes while they remain unaltered following *Kidins220* silencing in cultured WT astrocytes. These results are in striking contrast to those obtained for SNX27, which diminishes both in *Kidins220*<sup>ff</sup> and

*Kidins220*-silenced astrocytes, indicating a cell-autonomous and direct role of *Kidins220* on SNX27 regulation but not on VPS35.

Future studies will determine whether the genetic inactivation of *Snx27* or *Vps35* leads to AQP4 depletion and if restoration of SNX27-retromer activity in vivo can be of therapeutic interest to stabilise AQP4 levels and rescue ventriculomegaly in *Kidins220*-deficient mice or in other hydrocephalus or neurological disease models that may concur with AQP4 deficiency. We propose that AQP4 downregulation is critical for ventricular enlargement in *Kidins220*<sup>ff</sup> animals, but we cannot rule out that other proteins deregulated in these mice might also contribute to this phenotype. This could be the case of transient receptor potential vanilloid 4 (TRPV4), a cation channel upregulated in *Kidins220*<sup>-/-</sup> astrocytes [60] that together with AQP4 is essential for water cell-volume control in these cells [52].

*Kidins220* trafficking from the endosome to the plasma membrane or to the lysosome is regulated in HeLa cells by the SNX27-retromer [25], a complex responsible for the endosomal recycling of multiple cargos to the cellular surface [26]. Although regulation in the reverse direction (of SNX27-retromer levels by *Kidins220*) was unexpected, here we find that *Kidins220* deficiency downregulates SNX27 in vivo and in vitro, and VPS35 in vivo, likely through protein stabilization, as mRNA levels for both molecules are not substantially decreased. The possible role of *Kidins220* on the regulation of SNX27-retromer stability is extremely attractive and deserves further investigation.

Globally, our results point to *Kidins220* as a critical regulator of SNX27-retromer dependent endosomal sorting of multiple cargos. Accordingly, a genome-wide analysis performed in *Caenorhabditis elegans* identified *Kidins220* as a strong candidate regulator of endocytosis [61]. *Kidins220* and SNX27, therefore, regulate one another in an intriguing reciprocal 'feedback loop' that may result in a fine-tuning of endocytic recycling versus lysosomal degradation of various SNX27-retromer cargos. Whether *Kidins220* loss could affect AQP4 directly is an interesting issue difficult to study since *Kidins220* deficiency decreases both SNX27 and AQP4. Our studies using SNX27 silencing and rendering AQP4 downregulation, suggest that AQP4 downregulation in *Kidins220*-deficient cells and mice is mediated by SNX27 protein loss, but we cannot exclude that an additional, direct regulation of *Kidins220* on AQP4 (SNX27-independent) may also exist.

Here we have identified AQP4 as a novel SNX27-retromer cargo. AQP4 C-terminal amino acids constitute a canonical type I PDZ-L, but differ slightly with those defined as selective for SNX27 PDZ-binding bearing an acidic clamp between P-3 and P-5 [55]. Similar to other SNX27 cargos, such as the typical cargo GLUT1, or PTEN [62] and OTULIN [63], AQP4 PDZ-L does not contain



acidic residues at both P-3 and P-5, suggesting that selectivity and affinity of SNX27 for its cargos may rely not only on their C-terminal peptide but also on their global context.

*KIDINS220* heterozygous nonsense variants have been recently associated with SINO syndrome, a novel rare autosomal disease characterized by spastic paraplegia, intellectual disability, nystagmus and obesity in children [40]. Similar to *Kidins220<sup>ff</sup>* mice, the brain LVs and TV of these children are enlarged but not the FV [40]. Moreover, homozygous *KIDINS220* loss-of-function variants have been detected in foetuses that also present cerebral ventriculomegaly [41]. We anticipate that truncated Kidins220 forms lacking the PDZ-L, as that identified in SINO syndrome [40], will not interact with the SNX27-retromer complex. Recycling to the cell surface of Kidins220 variants devoid of PDZ-L would therefore be hampered and these variants would be mostly targeted for lysosomal degradation. Accordingly, this type of variant would not only greatly impair Kidins220 function at the cell surface and other intracellular compartments, but also drop its steady-state levels by increasing its degradation rate. Moreover, as the interaction of Kidins220 PDZ-L with SNX27 could be key for maintaining SNX27-retromer stability and levels, the lack of Kidins220 PDZ-L binding could destabilize SNX27 and therefore decrease its half-life. The global recycling of SNX27 cargos (like AQP4) to the cell surface would be consequently diminished, resulting in their increased lysosomal targeting and degradation. SINO syndrome, hydrocephalus and ventriculomegaly could thus be all retromer-related disorders.

The novel missense variants identified in *KIDINS220* gene in schizophrenic patients [37–39] could be also associated with cerebral ventricular enlargement in these individuals given it is a frequent feature in this psychiatric disorder [5, 6], a possibility that should be examined. Although it is currently unknown whether *KIDINS220* variants in SINO and schizophrenic patients could lead to similar defects in SNX27-retromer and AQP4 expression and brain water dyshomeostasis as found in *Kidins220* deficient mice, our data point at *Kidins220<sup>ff</sup>* mice as an attractive model to study SINO syndrome, Kidins220-linked schizophrenia and other neuropathologies accompanied by ventriculomegaly such as foetal/perinatal to adulthood onset forms of hydrocephalus.

The complex etiopathology of ventriculomegaly and hydrocephalus and the limited knowledge of the molecular mechanisms involved hinder the diagnostic, prognostic and therapeutic strategies for patients. There is an urgent need of appropriate tools for differential diagnosis and biomarkers for specific hydrocephalus types or different ventriculomegaly-associated diseases, especially in adults. The most common procedure to treat the large ventricular accumulation of CSF, the implantation of a ventricular

shunt, saves the life of many patients but the failure rate of this procedure is high and its outcome is not always positive. AQP4 downregulation had been shown at perivascular locations in iNPH patients [22, 23] and here we show that its expression and that of *KIDINS220* (but not S100 $\beta$ ) are substantially decreased at the ventricular ependymal lining, suggesting that loss of these proteins at the ependyma might also contribute to adult chronic hydrocephalus. Indeed, AQP4 deficiency in this region might account for the reported enhancement in transependymal CSF flow in iNPH patients [64] that also present glymphatic (glia-lymphatic) circulation system for brain waste clearance impairments [64, 65]. Since the glymphatic CSF circulation is controlled by AQP4 and is altered in iNPH and AD [11], our results prompt to investigate the participation of *KIDINS220* and SNX27-retromer in the function of this system, and in the dynamics and turnover of AQP4 and other cargos in iNPH and different hydrocephalus types, AD, and other neurodegenerative and neuropsychiatric disorders that concur with ventriculomegaly. Novel strategies designed to potentiate AQP4 levels in ventricular ependymal cells and astrocytes, including the use of viral vectors, molecules or compounds that enhance Kidins220 and/or SNX27-retromer expression or stabilization and therefore AQP4 recycling to the plasma membrane, could be promising therapeutic approaches to prevent or revert ventricular enlargement caused by AQP4 increased turnover.

**Acknowledgements** This work was supported by Spanish grants SAF2017-88885-R to TI and SAF2017-88881-R to MRC from the Spanish Ministerio de Economía y Competitividad/Agencia Estatal de Investigación/European Union Funds for Regional Development (MINECO/AEI/ FEDER, EU); by Comunidad de Madrid through the European Social Fund (ESF)-financed programme NEUROMETAB-CM (B2017/BMD-3700) to TI and AORTASANA-CM (B2017/BMD-3676) to MRC; by ‘La Caixa’ Banking Foundation project HR18-00068 to MRC; by Centro de Investigación Biomédica en Red de Enfermedades Neurodegenerativas (CIBERNED, Instituto de Salud Carlos III, Spain) CB06/05/1122 to TI and collaborative grant CIBERNED PI2018/06 to TI and IFa; by grant PID2019-104763RB-I00 and Ramón y Cajal programme contract (RYC-2014-15991), both from MINECO/AEI/FEDER (EU) to EP; by Wellcome Trust Senior Investigator Award (107116/Z/15/Z), the European Union’s Horizon 2020 Research and Innovation programme under grant agreement 739572 and a UK Dementia Research Institute Foundation award, all to GS; by grant PI19/00778 to AJJ from the Spanish Instituto de Salud Carlos III, co-funded by FEDER (EU); by Spanish grants from FEDER/Ministerio de Ciencia e Innovación (MICI)–AEI (SAF2017-86690-R), Network of Excellence iDIFFER (RED2018-102723-T), Instituto de Salud Carlos III (CIBERNED CB06/05/0086 and RETIC Terce RD16/0011/0017) and Generalitat Valenciana (Prometeo 2017/030) to IFa. ADP was funded by a Juan de la Cierva Formación programme contract (FJCI-2014-19673; MINECO) and CIBERNED; JP-U was contracted by SAF2017-88885-R grant; AS-S was contracted by grants CIBERNED-PI2015-2/06 and PI2018/06, and SAF2017-88885-R; AS-G was funded by a contract from B2017/BMD-3700 grant and LSMP by a PhD training contract (PRE2018-086989) associated to grant SAF2017-88885-R. The cost of this publication has been paid in part by FEDER (European Union Funds

for Regional Development) funds. We are particularly indebted to the patients and the Biobanks integrated in the Spanish National Biobanks Network, Biobank Banco de Tejidos CIEN (PT17/0015/0014), the HCB-IDIBAPS Biobank and Institute of Neuropathology Brain Bank-IDIBELL, for their collaboration in sample and data procurement. We are grateful to Professor M. Amiry-Moghaddam (University of Oslo, Norway) for his help with AQP4 reagents and methodological details, Professors P.J. Cullen (University of Bristol, UK) and F. Steinberg (Albert Ludwigs Universitaet Freiburg, Germany) for providing SNX27 plasmids. We also acknowledge M. Rodríguez-Martínez and T. Navarro for performing MRI studies; Drs. P. Lopez-Larrubia (IIBM, CSIC-UAM) and A. Martín (Achucarro Basque Center for Neuroscience, Bilbao, Spain) for advice in MRI analysis; L. García-Guerra, A. González-Martín and other laboratory members for help and suggestions; L. Sánchez-Ruiloba for technical assistance in confocal images analysis, L. Jiménez for taking care of mice colonies; and to core facilities at Instituto de Investigaciones Biomédicas 'Alberto Sols' de Madrid (IIBM, CSIC-UAM): Animal Care, Genomics, Confocal microscopy.

**Author contributions** TI, MRC and ADP conceived and designed the experiments, interpreted the data and wrote the paper with input from all authors. ADP, JP-U, AS-G, CL-M, AJJ, EP, LSMP, GC-G, BM-P, AS-S and MPS-C performed experiments, analysed, interpreted and discussed results. AJJ, FC, GS, IFe and IFa, contributed reagents, animals, materials or analysis tools, and made intellectual contributions to experimental design and discussion. All authors approved submission of this work.

## Compliance with ethical standards

**Conflict of interest** The authors declare no competing interests.

**Publisher's note** Springer Nature remains neutral with regard to jurisdictional claims in published maps and institutional affiliations.

**Open Access** This article is licensed under a Creative Commons Attribution 4.0 International License, which permits use, sharing, adaptation, distribution and reproduction in any medium or format, as long as you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons license, and indicate if changes were made. The images or other third party material in this article are included in the article's Creative Commons license, unless indicated otherwise in a credit line to the material. If material is not included in the article's Creative Commons license and your intended use is not permitted by statutory regulation or exceeds the permitted use, you will need to obtain permission directly from the copyright holder. To view a copy of this license, visit <http://creativecommons.org/licenses/by/4.0/>.

## References

1. Del Bigio MR. Neuropathology and structural changes in hydrocephalus. *Dev Disabil Res Rev.* 2010;16:16–22.
2. Oi S. Hydrocephalus research update-controversies in definition and classification of hydrocephalus. *Neurol Med Chir (Tokyo).* 2010;50:859–69.
3. Jimenez AJ, Dominguez-Pinos MD, Guerra MM, Fernandez-Llebrez P, Perez-Figares JM. Structure and function of the ependymal barrier and diseases associated with ependyma disruption. *Tissue Barriers.* 2014;2:e28426.
4. Leinonen V, Vanninen R, Rauramaa T. Cerebrospinal fluid circulation and hydrocephalus. *Handb Clin Neurol.* 2017;145:39–50.
5. Johnstone EC, Crow TJ, Frith CD, Husband J, Kreef L. Cerebral ventricular size and cognitive impairment in chronic schizophrenia. *Lancet.* 1976;2:924–6.
6. Kempton MJ, Stahl D, Williams SC, DeLisi LE. Progressive lateral ventricular enlargement in schizophrenia: a meta-analysis of longitudinal MRI studies. *Schizophr Res.* 2010;120:54–62.
7. Mak E, Su L, Williams GB, Firbank MJ, Lawson RA, Yamall AJ, et al. Longitudinal whole-brain atrophy and ventricular enlargement in nondemented Parkinson's disease. *Neurobiol Aging.* 2017;55:78–90.
8. Nestor SM, Rupsingh R, Borrie M, Smith M, Accomazzi V, Wells JL, et al. Ventricular enlargement as a possible measure of Alzheimer's disease progression validated using the Alzheimer's disease neuroimaging initiative database. *Brain.* 2008;131:2443–54.
9. Silverberg GD, Mayo M, Saul T, Rubenstein E, McGuire D. Alzheimer's disease, normal-pressure hydrocephalus, and senescent changes in CSF circulatory physiology: a hypothesis. *Lancet Neurol.* 2003;2:506–11.
10. Martin-Laez R, Valle-San Roman N, Rodriguez-Rodriguez EM, Marco-de Lucas E, Berciano Blanco JA, Vazquez-Barquero A. Current concepts on the pathophysiology of idiopathic chronic adult hydrocephalus: are we facing another neurodegenerative disease? *Neurologia.* 2018;33:449–58.
11. Reeves BC, Karimy JK, Kundishora AJ, Mestre H, Cerci HM, Matouk C, et al. Glymphatic system impairment in alzheimer's disease and idiopathic normal pressure hydrocephalus. *Trends Mol Med.* 2020;26:285–95.
12. Nielsen S, Nagelhus EA, Amiry-Moghaddam M, Bourque C, Agre P, Ottersen OP. Specialized membrane domains for water transport in glial cells: high-resolution immunogold cytochemistry of aquaporin-4 in rat brain. *J Neurosci.* 1997;17:171–80.
13. Rash JE, Yasumura T, Hudson CS, Agre P, Nielsen S. Direct immunogold labeling of aquaporin-4 in square arrays of astrocyte and ependymocyte plasma membranes in rat brain and spinal cord. *Proc Natl Acad Sci U.S.A.* 1998;95:11981–6.
14. Feng X, Papadopoulos MC, Liu J, Li L, Zhang D, Zhang H, et al. Sporadic obstructive hydrocephalus in Aqp4 null mice. *J Neurosci Res.* 2009;87:1150–5.
15. Bloch O, Auguste KI, Manley GT, Verkman AS. Accelerated progression of kaolin-induced hydrocephalus in aquaporin-4 deficient mice. *J Cereb Blood Flow Metab.* 2006;26:1527–37.
16. Iloff JJ, Wang M, Liao Y, Plogg BA, Peng W, Gundersen GA, et al. A paravascular pathway facilitates CSF flow through the brain parenchyma and the clearance of interstitial solutes, including amyloid beta. *Sci Transl Med.* 2012;4:147ra111.
17. Haj-Yasein NN, Vindedal GF, Eilert-Olsen M, Gundersen GA, Skare O, Laake P, et al. Glial-conditional deletion of aquaporin-4 (Aqp4) reduces blood-brain water uptake and confers barrier function on perivascular astrocyte endfeet. *Proc Natl Acad Sci U.S.A.* 2011;108:17815–20.
18. Vindedal GF, Thoren AE, Jensen V, Klungland A, Zhang Y, Holtzman MJ, et al. Removal of aquaporin-4 from glial and ependymal membranes causes brain water accumulation. *Mol Cell Neurosci.* 2016;77:47–52.
19. Nagelhus EA, Ottersen OP. Physiological roles of aquaporin-4 in brain. *Physiol Rev.* 2013;93:1543–62.
20. Papadopoulos MC, Verkman AS. Aquaporin water channels in the nervous system. *Nat Rev Neurosci.* 2013;14:265–77.
21. Nakada T, Kwee IL. Fluid dynamics inside the brain barrier: current concept of interstitial flow, glymphatic flow, and cerebrospinal fluid circulation in the brain. *Neuroscientist.* 2019;25:155–66.
22. Eide PK, Hansson HA. Astroglial and impaired aquaporin-4 and dystrophin systems in idiopathic normal pressure hydrocephalus. *Neuropathol Appl Neurobiol.* 2018;44:474–90.

23. Hasan-Olive MM, Enger R, Hansson HA, Nagelhus EA, Eide PK. Loss of perivascular aquaporin-4 in idiopathic normal pressure hydrocephalus. *Glia*. 2019;67:91–100.
24. Wang X, Zhou Y, Wang J, Tseng IC, Huang T, Zhao Y, et al. SNX27 deletion causes hydrocephalus by impairing ependymal cell differentiation and ciliogenesis. *J Neurosci*. 2016;36:12586–97.
25. Steinberg F, Gallon M, Winfield M, Thomas EC, Bell AJ, Heesom KJ, et al. A global analysis of SNX27-retromer assembly and cargo specificity reveals a function in glucose and metal ion transport. *Nat Cell Biol*. 2013;15:461–71.
26. Cullen PJ, Steinberg F. To degrade or not to degrade: mechanisms and significance of endocytic recycling. *Nat Rev Mol Cell Biol*. 2018;19:679–96.
27. Zhang H, Huang T, Hong Y, Yang W, Zhang X, Luo H, et al. The retromer complex and sorting nexins in neurodegenerative diseases. *Front Aging Neurosci*. 2018;10:79.
28. Iglesias T, Cabrera-Poch N, Mitchell MP, Naven TJ, Rozengurt E, Schiavo G. Identification and cloning of Kidins220, a novel neuronal substrate of protein kinase D. *J Biol Chem*. 2000;275:40048–56.
29. Kong H, Boulter J, Weber JL, Lai C, Chao MV. An evolutionarily conserved transmembrane protein that is a novel downstream target of neurotrophin and ephrin receptors. *J Neurosci*. 2001;21:176–85.
30. Neubrand VE, Cesca F, Benfenati F, Schiavo G. Kidins220/ARMS as a functional mediator of multiple receptor signalling pathways. *J Cell Sci*. 2012;125:1845–54.
31. Scholz-Starke J, Cesca F. Stepping out of the shade: control of neuronal activity by the scaffold protein kidins220/ARMS. *Front Cell Neurosci*. 2016;10:68.
32. Lopez-Menendez C, Gamir-Morralla A, Jurado-Arjona J, Higuero AM, Campanero MR, Ferrer I, et al. Kidins220 accumulates with tau in human Alzheimer's disease and related models: modulation of its calpain-processing by GSK3beta/PP1 imbalance. *Hum Mol Genet*. 2013;22:466–82.
33. Gamir-Morralla A, Lopez-Menendez C, Ayuso-Dolado S, Tejada GS, Montaner J, Rosell A, et al. Development of a neuroprotective peptide that preserves survival pathways by preventing Kidins220/ARMS calpain processing induced by excitotoxicity. *Cell Death Dis*. 2015;6:e1939.
34. Gamir-Morralla A, Belbin O, Fortea J, Alcolea D, Ferrer I, Lleó A, et al. Kidins220 correlates with Tau in Alzheimer's disease brain and cerebrospinal fluid. *J Alzheimers Dis*. 2017;55:1327–33.
35. Sebastian-Serrano A, Simon-Garcia A, Belmonte-Alfaro A, Pose-Utrilla J, Santos-Galindo M, Del Puerto A, et al. Differential regulation of Kidins220 isoforms in Huntington's disease. *Brain Pathol*. 2020;30:120–36.
36. Lopez-Benito S, Sanchez-Sanchez J, Brito V, Calvo L, Lisa S, Torres-Valle M, et al. Regulation of BDNF release by ARMS/Kidins220 through modulation of synaptotagmin-IV Levels. *J Neurosci*. 2018;38:5415–28.
37. Kranz TM, Goetz RR, Walsh-Messinger J, Goetz D, Antonius D, Dolgalev I, et al. Rare variants in the neurotrophin signaling pathway implicated in schizophrenia risk. *Schizophr Res*. 2015;168:421–8.
38. Malaspina D, Kranz TM, Heguy A, Harroch S, Mazgaj R, Rothman K, et al. Prefrontal neuronal integrity predicts symptoms and cognition in schizophrenia and is sensitive to genetic heterogeneity. *Schizophr Res*. 2016;172:94–100.
39. Kranz TM, Berns A, Shields J, Rothman K, Walsh-Messinger J, Goetz RR, et al. Phenotypically distinct subtypes of psychosis accompany novel or rare variants in four different signaling genes. *EBioMedicine*. 2016;6:206–14.
40. Josifova DJ, Monroe GR, Tessadori F, de Graaff E, van der Zwaag B, Mehta SG, et al. Heterozygous KIDINS220/ARMS nonsense variants cause spastic paraplegia, intellectual disability, nystagmus, and obesity. *Hum Mol Genet*. 2016;25:2158–67.
41. Mero IL, Mork HH, Sheng Y, Blomhoff A, Opheim GL, Erichsen A, et al. Homozygous KIDINS220 loss-of-function variants in fetuses with cerebral ventriculomegaly and limb contractures. *Hum Mol Genet*. 2017;26:3792–6.
42. Santpere G, Nieto M, Puig B, Ferrer I. Abnormal Sp1 transcription factor expression in Alzheimer disease and tauopathies. *Neurosci Lett*. 2006;397:30–4.
43. Cesca F, Yabe A, Spencer-Dene B, Scholz-Starke J, Medrihan L, Maden CH, et al. Kidins220/ARMS mediates the integration of the neurotrophin and VEGF pathways in the vascular and nervous systems. *Cell Death Differ*. 2012;19:194–208.
44. Cesca F, Yabe A, Spencer-Dene B, Arrigoni A, Al-Qatari M, Henderson D, et al. Kidins220/ARMS is an essential modulator of cardiovascular and nervous system development. *Cell Death Dis*. 2011;2:e226.
45. Lopez-Menendez C, Simon-Garcia A, Gamir-Morralla A, Pose-Utrilla J, Lujan R, Mochizuki N, et al. Excitotoxic targeting of Kidins220 to the Golgi apparatus precedes calpain cleavage of Rap1-activation complexes. *Cell Death Dis*. 2019;10:535.
46. Mirzadeh Z, Doetsch F, Sawamoto K, Wichterle H, Alvarez-Buylla A. The subventricular zone en-face: wholemount staining and ependymal flow. *J Vis Exp*. 2010; J Vis Exp. 2010; 39:e1938.
47. Del Bigio MR. Ependymal cells: biology and pathology. *Acta Neuropathol*. 2010;119:55–73.
48. Roales-Bujan R, Paez P, Guerra M, Rodriguez S, Vio K, Ho-Plagaro A, et al. Astrocytes acquire morphological and functional characteristics of ependymal cells following disruption of ependyma in hydrocephalus. *Acta Neuropathol*. 2012;124:531–46.
49. Raponi E, Agenes F, Delphin C, Assard N, Baudier J, Legraverend C, et al. S100B expression defines a state in which GFAP-expressing cells lose their neural stem cell potential and acquire a more mature developmental stage. *Glia*. 2007;55:165–77.
50. Jacquet BV, Salinas-Mondragon R, Liang H, Therit B, Buie JD, Dykstra M, et al. FoxJ1-dependent gene expression is required for differentiation of radial glia into ependymal cells and a subset of astrocytes in the postnatal brain. *Development*. 2009;136:4021–31.
51. Redmond SA, Figueres-Onate M, Obernier K, Nascimento MA, Parraguez JI, Lopez-Mascaraque L, et al. Development of ependymal and postnatal neural stem cells and their origin from a common embryonic progenitor. *Cell Rep*. 2019;27:429–41. e423
52. Benfenati V, Caprini M, Dovizio M, Mylonakou MN, Ferroni S, Ottersen OP, et al. An aquaporin-4/transient receptor potential vanilloid 4 (AQP4/TRPV4) complex is essential for cell-volume control in astrocytes. *Proc Natl Acad Sci U.S.A.* 2011;108:2563–8.
53. Madrid R, Le Maout S, Barrault MB, Janvier K, Benichou S, Merot J. Polarized trafficking and surface expression of the AQP4 water channel are coordinated by serial and regulated interactions with different clathrin-adaptor complexes. *EMBO J*. 2001;20:7008–21.
54. McNally KE, Faulkner R, Steinberg F, Gallon M, Ghai R, Pim D, et al. Retriever is a multiprotein complex for retromer-independent endosomal cargo recycling. *Nat Cell Biol*. 2017;19:1214–25.
55. Clairfeuille T, Mas C, Chan AS, Yang Z, Tello-Lafoz M, Chandra M, et al. A molecular code for endosomal recycling of phosphorylated cargos by the SNX27-retromer complex. *Nat Struct Mol Biol*. 2016;23:921–32.
56. Neely JD, Amiry-Moghaddam M, Ottersen OP, Froehner SC, Agre P, Adams ME. Syntrophin-dependent expression and

- localization of Aquaporin-4 water channel protein. *Proc Natl Acad Sci U.S.A.* 2001;98:14108–13.
57. Nakahama K, Fujioka A, Nagano M, Satoh S, Furukawa K, Sasaki H, et al. A role of the C-terminus of aquaporin 4 in its membrane expression in cultured astrocytes. *Genes Cells.* 2002;7:731–41.
  58. Li X, Kong H, Wu W, Xiao M, Sun X, Hu G. Aquaporin-4 maintains ependymal integrity in adult mice. *Neuroscience.* 2009;162:67–77.
  59. Wu KY, Tang FL, Lee D, Zhao Y, Song H, Zhu XJ, et al. Ependymal Vps35 promotes ependymal cell differentiation and survival, suppresses microglial activation, and prevents neonatal hydrocephalus. *J Neurosci.* 2020;40:3862–79.
  60. Jaudon F, Chiacchiarettla M, Albin M, Ferroni S, Benfenati F, Cesca F. Kidins220/ARMS controls astrocyte calcium signaling and neuron-astrocyte communication. *Cell Death Differ.* 2020;27:1505–19.
  61. Balklava Z, Pant S, Fares H, Grant BD. Genome-wide analysis identifies a general requirement for polarity proteins in endocytic traffic. *Nat Cell Biol.* 2007;9:1066–73.
  62. Shinde SR, Maddika S. PTEN regulates glucose transporter recycling by impairing SNX27 retromer assembly. *Cell Rep.* 2017;21:1655–66.
  63. Stangl A, Elliott PR, Pinto-Fernandez A, Bonham S, Harrison L, Schaub A, et al. Regulation of the endosomal SNX27-retromer by OTULIN. *Nat Commun.* 2019;10:4320.
  64. Ringstad G, Vatnehol SAS, Eide PK. Glymphatic MRI in idiopathic normal pressure hydrocephalus. *Brain.* 2017;140:2691–705.
  65. Eide PK, Ringstad G. Delayed clearance of cerebrospinal fluid tracer from entorhinal cortex in idiopathic normal pressure hydrocephalus: a glymphatic magnetic resonance imaging study. *J Cereb Blood Flow Metab.* 2019;39:1355–68.

## Affiliations

Ana del Puerto<sup>1,2,16,16</sup> · Julia Pose-Utrilla<sup>1,2</sup> · Ana Simón-García<sup>1,2</sup> · Celia López-Menéndez<sup>1,2</sup> · Antonio J. Jiménez<sup>3,4</sup> · Eva Porlan<sup>5,6,7</sup> · Luis S. M. Pajuelo<sup>1,2</sup> · Guillermo Cano-García<sup>1</sup> · Beatriz Martí-Prado<sup>8</sup> · Álvaro Sebastián-Serrano<sup>1,2,17,17</sup> · Marina P. Sánchez-Carralero<sup>1,2</sup> · Fabrizia Cesca<sup>9</sup> · Giampietro Schiavo<sup>10,11</sup> · Isidro Ferrer<sup>12,13,14</sup> · Isabel Fariñas<sup>2,8</sup> · Miguel R. Campanero<sup>15</sup> · Teresa Iglesias<sup>16</sup>

<sup>1</sup> Instituto de Investigaciones Biomédicas “Alberto Sols”, Consejo Superior de Investigaciones Científicas-Universidad Autónoma de Madrid (CSIC-UAM), Madrid, Spain

<sup>2</sup> Centro de Investigación Biomédica en Red de Enfermedades Neurodegenerativas (CIBERNED), Instituto de Salud Carlos III, Madrid, Spain

<sup>3</sup> Departamento de Biología Celular, Genética y Fisiología, Facultad de Ciencias, Universidad de Málaga, Bulevar Louis Pasteur, Málaga, Spain

<sup>4</sup> Instituto de Investigación Biomédica de Málaga (IBIMA), Instituto de Salud Carlos III, Málaga, Spain

<sup>5</sup> Centro de Biología Molecular “Severo Ochoa” (CSIC-UAM), Madrid, Spain

<sup>6</sup> Departamento de Biología Molecular, Facultad de Ciencias, UAM, Madrid, Spain

<sup>7</sup> Instituto de Investigación Hospital Universitario La Paz (IdiPAZ), Instituto de Salud Carlos III, Madrid, Spain

<sup>8</sup> Departamento de Biología Celular, Biología Funcional y Antropología Física, Universidad de Valencia, Burjassot, Spain

<sup>9</sup> Department of Life Sciences, University of Trieste, Trieste, Italy

<sup>10</sup> Department of Neuromuscular Disorders, UCL Institute of Neurology, University College London, London, UK

<sup>11</sup> UK Dementia Research Institute, University College London, London, UK

<sup>12</sup> Departamento de Patología y Terapéutica Experimental, Universidad de Barcelona, Barcelona, Spain

<sup>13</sup> Instituto de Neurociencias, Universidad de Barcelona, Hospitalet de Llobregat, Barcelona, Spain

<sup>14</sup> Servicio de Anatomía Patológica, Hospital Universitario de Bellvitge, Carrer de la Feixa Llarga, Barcelona, Spain

<sup>15</sup> Centro de Investigación Biomédica en Red en Enfermedades Cardiovasculares (CIBERCV), Instituto de Salud Carlos III, Madrid, Spain

<sup>16</sup> Present address: Departamento de Biotecnología, Instituto Nacional de Investigación y Tecnología Agraria y Alimentaria (INIA), Madrid, Spain

<sup>17</sup> Present address: Departamento de Bioquímica y Biología Molecular, Facultad de Veterinaria, Universidad Complutense de Madrid, Madrid, Spain